TargTex SA is a portuguese biotech company founded in 2019 that emerged from a blended academic research and medical environment. Its basic technology was developed in Gonçalo Bernardes research lab at Instituto de Medicina Molecular (iMM) of the University of Lisbon. Its foundation is based on an artificial intelligence algorithm created by one of the founding members that can decipher relationships between biological targets and molecules of interest. Hence, it was possible to identify an unexplored target for a daunting pathology – Glioblastoma Multiforme (GBM). Considering GBM’s particularities, the company is developing a solution based on a hydrogel to be used as adjunct-to-surgery in a single dose therapy. On a long-term perspective, TargTex aims to develop clinical candidates for different oncological indications. The GBM pilot project is the first step to become a sustainable company that will enable the development of other anticancer candidates.